Clinical trial · Interventional
STHLM3 - Prostate Cancer Diagnostic Trial
NCT03639649CI-TRIAL-00034483STHLM3completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
STHLM3 is a paired diagnostic trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for aggressive prostate cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| STHLM3 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- STHLM3
- interventionNames
- Diagnostic Test: STHLM3
- type
- ACTIVE_COMPARATOR
- label
- PSA
- interventionNames
- Diagnostic Test: STHLM3
Primary outcomes (1)
- measure
- Number of biopsies
- timeFrame
- Recorded directly after biopsy
Secondary outcomes (3)
- measure
- Number of Gleason Score ≥ 7
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
- Maximum age
- 69 Years
Show eligibility criteria text
Inclusion Criteria: * Age 50-69 * Residential address in Stockholm County Exclusion Criteria: * Previous Prostate Cancer Diagnosis * Not able to comprehend inform consent material
References
Publications (0)
Data not yet available
No reference posted for this study.